Analyst consensus rating
BioCryst Pharmaceuticals Analyst Rating: Buy
Direct answer
BioCryst Pharmaceuticals's consensus rating is Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.73.
Forecast evidence checked October 17, 2026.
Get free BioCryst Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.79
- Average price target
- $20.73
- High price target
- $32.00
- Low price target
- $11.00
- Low target gap
- +41.2%
- Target upside
- +166.1%
- High target gap
- +310.8%
- Target range width
- 269.6%
- Consensus rating
- Buy
- Analysts
- 11
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $20.73.
How far are BioCryst Pharmaceuticals's low and high targets from the recorded price?
The low target implies +41.2%, while the high target implies +310.8%.
How many analysts are included in BioCryst Pharmaceuticals's consensus?
The verified consensus includes 11 analysts.
How is BioCryst Pharmaceuticals's target upside or downside calculated?
The average target of $20.73 is divided by the recorded price of $7.79, then one is subtracted to produce +166.1%. This does not guarantee a future return.
When was BioCryst Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.